Corporate information

Home

Born from the Ksilink Association’s proven track record, we are now on a bold mission to become Europe’s leading patient-centered engine for drug discovery.

The Ksilink Association has been created in 2015 with the mission to foster patient-based drug discovery in the heart of Europe through collaborations with a network of renowned partners from academia and biotechs. Our company, Ksilink Services SAS, has emerged from this dynamic ecosystem with a dedicated team equipped with cutting-edge expertise and state-of-the-art technology, driven by the ambition to become Europe’s leading patient-centered discovery engine for novel drug candidates.

Name: Ksilink

Legal name: Ksilink Services SAS

Form: Limited company (“SAS” stands for “Société par actions simplifiée”)

Creation: December 7, 2021

Share capital: 900,000€

Registered: in France under SIREN number 908 717 796

VAT number: FR22908717796

Headquarters: 16 rue Ankara 67000 Strasbourg, France

President: Ksilink Association, represented by Alain Beretz

CEO: Antoine de Lacombe

Information available as of 29.08.2025

Corporate information

Born from the Ksilink Association’s proven track record, we are now on a bold mission to become Europe’s leading patient-centered engine for drug discovery.​

Born from the Ksilink Association’s proven track record, we are now on a bold mission to become Europe’s leading patient-centered engine for drug discovery.